Wang, Ping
Wang, Juan https://orcid.org/0000-0003-0933-3744
Wang, Qixuan
Youngblood, Mark W.
Cheng, Yang https://orcid.org/0009-0002-5114-5456
Tao, Bo https://orcid.org/0000-0002-5490-4668
Wong, Josiah Hiu-Yuen https://orcid.org/0009-0007-5176-2485
Luan, Yu https://orcid.org/0000-0003-1778-9071
Yu, Shaojun
Swaroop, Alok
Nandoliya, Khizar R.
Najem, Hinda https://orcid.org/0000-0003-4432-9708
Fu, Yihao
McCortney, Kathleen
Zhang, Di https://orcid.org/0000-0001-8466-9868
Diao, Yarui https://orcid.org/0000-0001-5842-4082
Heimberger, Amy B. https://orcid.org/0000-0002-9970-8695
Sonabend, Adam M.
Horbinski, Craig M. https://orcid.org/0000-0001-8340-9992
Fan, Rong https://orcid.org/0000-0001-7805-8059
Yue, Feng https://orcid.org/0000-0002-7954-5462
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM124820)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (1R01HG009906)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (R01HG011207)
U.S. Department of Defense (CA230856)
CU | National Cancer Institute, Cairo University (T32 CA009560)
CU | National Cancer Institute, Cairo University (T32 CA070085)
Article History
Received: 11 September 2025
Accepted: 3 August 2026
First Online: 1 September 2026
Ethics
Competing interests: A provisional patent application related to this work has been filed by Northwestern University and Yale University. F.Y. is a scientific co-founder of Sariant Therapeutics. R.F. is a scientific founder and adviser for IsoPlexis, Singleron Biotechnologies and AtlasXomics. The interests of R.F. were reviewed and managed by the Yale University Provost’s Office in accordance with the university’s conflict of interest policies. The other authors declare no competing interests.